Completion of Acquisition
23 Diciembre 2004 - 11:00AM
UK Regulatory
RNS Number:8225G
Cytomyx Holdings PLC
23 December 2004
For Immediate Release 23 December 2004
Cytomyx Holdings Plc
Completion of Clinomics Acquisition
The Company is pleased to announce that, further to the passing of the
resolution approving the amendment of the terms of the Clinomics Biosciences,
Inc. ("Clinomics") acquisition to allow an accelerated allotment of the deferred
consideration shares, 1,777,778 ordinary shares of 2.5 pence each in the Company
("Ordinary Shares") have been issued as deferred consideration for the
acquisition and the Company has in addition issued the final tranche of the
initial consideration for Clinomics, comprising 384,835 ordinary shares, which
were with held pending agreement of completion accounts.
As a result the Company has applied for an aggregate of 2,162,613 Ordinary
Shares to be admitted to trading on AIM with effect from 29 December 2004.
Following this issue the Company has 43,954,971 Ordinary Shares in issue.
For further information, please contact:
Cytomyx Holdings plc
Mike Kerins, Chief Executive 01223 508191
Buchanan Communications 020 7466 5000
Mark Court/Mary-Jane Johnson
The Wall Street Group, Inc. +1 212 888 4848
Ron Stabiner
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQQKNKPABDDCBB
Cytomyx (LSE:CYX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cytomyx (LSE:CYX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Cytomyx Hldgs (London Stock Exchange): 0 recent articles
Más de Cytomyx Hldgs Plc Artículos de Noticias